Souhaitez-vous accéder aux communiqués récents ?

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), Canada’s only 100% volunteer-driven charity dedicated exclusively to funding brain cancer research nationwide to award $75,000 to...

TORONTO, May 12, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), Canada’s only 100% volunteer-driven charity dedicated exclusively to funding brain cancer research nationwide is proud to...

- Interim results from the first three brain cancer patients treated; two of whom demonstrated complete response, with total disappearance of all enhancing tumor lesions, per multiple MRI scans since...

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

• Former Oxford Pro-Vice-Chancellor for Innovation and former Head of Biology at GSK to lead company’s R&D• Longstanding Scientific Advisory Board Chair steps into an expanded leadership role to...

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Tumor Models Market Report 2026" has been added to ResearchAndMarkets.com's offering. The tumor models market has been experiencing rapid growth,...

EO2401 in vivo immune therapy + nivolumab +/- bevacizumab shows survival benefit in first recurrent glioblastomaData presented at 2025 SNO conference by lead investigator Paris, France – 2 DECEMBER...

Kelyniam received a exclusive U.S. license from Evonik to market VESTAKEEP® Fusion, a bi-calcium phosphate-infused PEEK material, for cranial implants

BPGbio has completed phase 2b enrollment in late August this year for treatment of GBM with BPM31510Data further validate the MOA of BPM31510’s direct targeting of mitochondrial redox machinery to...

Transpire Bio today announced that the U.S. FDA has granted orphan drug designation (ODD) for two of its products in development.